Chang, Vicky C. http://orcid.org/0000-0002-2528-9387
Khan, Ali A. http://orcid.org/0000-0002-4250-8828
Huang, Wen-Yi http://orcid.org/0000-0002-4440-3368
Katki, Hormuzd A.
Purdue, Mark P.
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Hofmann, Jonathan N. http://orcid.org/0000-0002-1043-5812
Article History
Received: 19 November 2021
Revised: 25 February 2022
Accepted: 3 March 2022
First Online: 1 April 2022
Competing interests
: OL has received research funding from the National Institutes of Health, U.S. Food and Drug Administration, Multiple Myeloma Research Foundation, International Myeloma Foundation, Leukemia and Lymphoma Society, Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, and Karyopharm; honoraria and ad boards from Adaptive, Amgen, Binding Site, Bristol Myers Squibb (BMS), Celgene, Cellectis, Glenmark, Janssen, Juno, and Pfizer; and serves on independent data monitoring committees for clinical trials led by Takeda, Merck, and Janssen. All other authors declare no conflict of interest.